• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

基于选定药物代谢基因的代谢表型对 EMPAR 研究人群进行评估。

Evaluation of the EMPAR study population on the basis of metabolic phenotypes of selected pharmacogenes.

机构信息

Research Division, Federal Institute for Drugs and Medical Devices, Bonn, North Rhine-Westphalia, Germany.

German Center for Neurodegenerative Diseases (DZNE), Bonn, North Rhine-Westphalia, Germany.

出版信息

Pharmacogenomics J. 2022 Mar;22(2):136-144. doi: 10.1038/s41397-022-00268-6. Epub 2022 Jan 31.

DOI:10.1038/s41397-022-00268-6
PMID:35102241
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8975744/
Abstract

The impact of genetic variability of pharmacogenes as a possible risk factor for adverse drug reactions is elucidated in the EMPAR (Einfluss metabolischer Profile auf die Arzneimitteltherapiesicherheit in der Routineversorgung/English: influence of metabolic profiles on the safety of drug therapy in routine care) study. EMPAR evaluates possible associations of pharmacogenetically predicted metabolic profiles relevant for the metabolism of frequently prescribed cardiovascular drugs. Based on a German study population of 10,748 participants providing access to healthcare claims data and DNA samples for pharmacogenetic assessment, first analyses were performed and evaluated. The aim of this first evaluation was the characterization of the study population with regard to general parameters such as age, gender, comorbidity, and polypharmacy at baseline (baseline year) as well as important combinations of cardiovascular drugs with relevant genetic variants and predicted metabolic phenotypes. The study was registered in the German Clinical Trials Register (DRKS) on July 6, 2018 (DRKS00013909).

摘要

在 EMPAR（Einfluss metabolischer Profile auf die Arzneimitteltherapiesicherheit in der Routineversorgung/English: influence of metabolic profiles on the safety of drug therapy in routine care）研究中，阐明了药物基因遗传变异性作为不良反应的可能危险因素的影响。EMPAR 评估了与经常开处方的心血管药物代谢相关的药物基因预测代谢谱的可能关联。基于为药物基因评估提供医疗保健索赔数据和 DNA 样本的 10748 名德国研究参与者的研究人群，首先进行了分析和评估。本次评估的目的是描述研究人群的一般参数，例如基线（基线年）时的年龄、性别、合并症和多药治疗情况，以及具有相关遗传变异和预测代谢表型的重要心血管药物组合。该研究于 2018 年 7 月 6 日在德国临床试验注册处（DRKS）注册（DRKS00013909）。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebe1/8975744/69bbe87d6d93/41397_2022_268_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebe1/8975744/22f483c85c77/41397_2022_268_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebe1/8975744/c808a8888798/41397_2022_268_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebe1/8975744/666e4cff0cb2/41397_2022_268_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebe1/8975744/a25a4bd29e78/41397_2022_268_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebe1/8975744/69bbe87d6d93/41397_2022_268_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebe1/8975744/22f483c85c77/41397_2022_268_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebe1/8975744/c808a8888798/41397_2022_268_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebe1/8975744/666e4cff0cb2/41397_2022_268_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebe1/8975744/a25a4bd29e78/41397_2022_268_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebe1/8975744/69bbe87d6d93/41397_2022_268_Fig5_HTML.jpg

相似文献

1
Evaluation of the EMPAR study population on the basis of metabolic phenotypes of selected pharmacogenes.基于选定药物代谢基因的代谢表型对 EMPAR 研究人群进行评估。
Pharmacogenomics J. 2022 Mar;22(2):136-144. doi: 10.1038/s41397-022-00268-6. Epub 2022 Jan 31.
2
The influence of age, gender and pharmacogenetic profiles on the perspective on medicines in the German EMPAR study.德国 EMPAR 研究中年龄、性别和药物遗传学特征对药物认知的影响。
PLoS One. 2024 Oct 10;19(10):e0311267. doi: 10.1371/journal.pone.0311267. eCollection 2024.
3
Influence of metabolic profiles on the safety of drug therapy in routine care in Germany: protocol of the cohort study EMPAR.代谢谱对德国常规护理中药物治疗安全性的影响：EMPAR 队列研究方案。
BMJ Open. 2020 Apr 27;10(4):e032624. doi: 10.1136/bmjopen-2019-032624.
4
Individualized versus standardized risk assessment in patients at high risk for adverse drug reactions (IDrug) - study protocol for a pragmatic randomized controlled trial.个体化与标准化风险评估在药物不良反应高风险患者中的应用（IDrug）——一项实用随机对照试验的研究方案
BMC Fam Pract. 2016 Apr 26;17:49. doi: 10.1186/s12875-016-0447-6.
5
Prevalence of exposure to pharmacogenetic drugs by the Saudis treated at the health care centers of the Ministry of National Guard.沙特国民卫队医疗中心治疗的沙特人接触药物遗传学药物的患病率。
Saudi Pharm J. 2022 Aug;30(8):1181-1192. doi: 10.1016/j.jsps.2022.06.013. Epub 2022 Jun 22.
6
Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing.药物诱导的尖端扭转型室性心动过速的药物遗传学方面：改善临床药物开发和处方的潜在工具。
Drug Saf. 2004;27(3):145-72. doi: 10.2165/00002018-200427030-00001.
7
[Drawing up guidelines for the attendance of physical health of patients with severe mental illness].[制定重症精神疾病患者身体健康检查指南]
Encephale. 2009 Sep;35(4):330-9. doi: 10.1016/j.encep.2008.10.014. Epub 2009 Jul 9.
8
[State of the art of pharmacogenetic diagnostics in drug therapy].[药物治疗中药理基因诊断的现状]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2006 Oct;49(10):995-1003. doi: 10.1007/s00103-006-0045-1.
9
Genetic Variation among Pharmacogenes in the Sardinian Population.撒丁岛人群中药物代谢基因的遗传变异。
Int J Mol Sci. 2022 Sep 2;23(17):10058. doi: 10.3390/ijms231710058.
10
Towards Pharmacogenomics-Driven Medication Risk Assessment in People with Polypharmacy.迈向多重用药人群中药物基因组学驱动的用药风险评估
Stud Health Technol Inform. 2018;247:880-884.

引用本文的文献

1
The influence of age, gender and pharmacogenetic profiles on the perspective on medicines in the German EMPAR study.德国 EMPAR 研究中年龄、性别和药物遗传学特征对药物认知的影响。
PLoS One. 2024 Oct 10;19(10):e0311267. doi: 10.1371/journal.pone.0311267. eCollection 2024.

本文引用的文献

1
Genetic polymorphisms of cytochrome P450 enzymes: CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in the Croatian population.细胞色素P450酶的基因多态性：克罗地亚人群中的CYP2C9、CYP2C19、CYP2D6、CYP3A4和CYP3A5
Drug Metab Pers Ther. 2017 Mar 1;32(1):11-21. doi: 10.1515/dmpt-2016-0024.
2
Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands.荷兰可预防的药物相关住院情况的发生率及风险因素
Arch Intern Med. 2008 Sep 22;168(17):1890-6. doi: 10.1001/archinternmed.2008.3.